Lytix Biopharma partner to present VP-315 data at SITC 2025

Lytix Biopharma AS announced its licensing partner, Verrica Pharmaceuticals Inc., will present new data from its Phase 2 clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, scheduled for November 5–9, 2025. The data, focusing on local immune activation in the tumor microenvironment following VP-315 treatment for basal cell carcinoma (BCC), will be presented in both oral and poster sessions. Dr. Kenneth Tsai from the Moffitt Cancer Center will deliver the oral presentation on November 7.

The abstract will offer additional insights into immune response activation in BCC patients, building upon previously reported primary clinical outcomes. Lytix Biopharma chief executive, Øystein Rekdal, expressed satisfaction with the selection of Verrica’s trial for oral presentation, highlighting the potential of Lytix’s oncolytic peptide technology.

VP-315 is licensed to Verrica for specific dermatologic oncology indications, including basal cell carcinoma, while Lytix retains rights for all other cancer indications. Lytix Biopharma, a clinical-stage biotech company developing host-defense peptide-derived molecules to boost anti-cancer immunity, is listed on Euronext Growth Oslo.